Department of Health Sciences, University of Florence.
Pathological Histology and Molecular Diagnostics Unit, Careggi University Hospital.
Anticancer Drugs. 2024 Jan 1;35(1):76-80. doi: 10.1097/CAD.0000000000001517. Epub 2023 Mar 10.
Lung cancer is the malignancy with the highest morbidity and mortality worldwide. Approximately 60% of non-small cell lung cancer (NSCLC) presents driver alterations most of which are targetable. Nowadays, limited clinical data are available regarding the efficacy of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with NSCLC harboring uncommon EGFR mutations, considering their heterogeneity. Herein, we report a rare case of EGFR-mutated lung adenocarcinoma which has developed into squamous cell carcinoma with uncommon EGFR (Ex18) compound mutations and phosphatidylinositol 3-kinase mutation receiving afatinib at the forefront.
肺癌是全球发病率和死亡率最高的恶性肿瘤。约 60%的非小细胞肺癌（NSCLC）存在驱动改变，其中大多数是可靶向的。目前，对于 NSCLC 患者中罕见的 EGFR 突变患者，由于其异质性，有关表皮生长因子受体（EGFR）酪氨酸激酶抑制剂疗效的临床数据有限。在此，我们报告了一例罕见的 EGFR 突变肺腺癌病例，该病例发展为具有罕见 EGFR（外显子 18）复合突变和磷脂酰肌醇 3-激酶突变的鳞状细胞癌，接受阿法替尼的一线治疗。
